280 related articles for article (PubMed ID: 18364726)
1. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Popat S; Smith IE
Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
3. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
4. Clinical cardiac tolerability of trastuzumab.
Perez EA; Rodeheffer R
J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
[TBL] [Abstract][Full Text] [Related]
5. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
Ewer MS; Ewer SM
J Clin Oncol; 2010 Sep; 28(25):3901-4. PubMed ID: 20679626
[No Abstract] [Full Text] [Related]
6. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
7. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
Ewer MS; Tan-Chiu E
J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
[No Abstract] [Full Text] [Related]
8. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
9. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab versus lapatinib: the cardiac side of the story.
Azim H; Azim HA; Escudier B
Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.
Sengupta PP; Northfelt DW; Gentile F; Zamorano JL; Khandheria BK
Mayo Clin Proc; 2008 Feb; 83(2):197-203. PubMed ID: 18241629
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-associated cardiotoxicity.
Keefe DL
Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-induced cardiotoxicity.
Moss LS; Starbuck MF; Mayer DK; Harwood EB; Glotzer J
Oncol Nurs Forum; 2009 Nov; 36(6):676-85. PubMed ID: 19887355
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab cardio-oncology: lessons learned.
Frankel C
Clin J Oncol Nurs; 2010 Oct; 14(5):630-40. PubMed ID: 20880820
[TBL] [Abstract][Full Text] [Related]
15. Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter.
Morris PG; Hudis CA
Breast Cancer Res Treat; 2011 Jun; 127(2):585-6. PubMed ID: 18791822
[No Abstract] [Full Text] [Related]
16. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
17. Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?
Davidson A; Gelmon K
Future Oncol; 2011 Jan; 7(1):37-55. PubMed ID: 21174537
[TBL] [Abstract][Full Text] [Related]
18. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
van Hasselt JG; Boekhout AH; Beijnen JH; Schellens JH; Huitema AD
Clin Pharmacol Ther; 2011 Jul; 90(1):126-32. PubMed ID: 21633346
[TBL] [Abstract][Full Text] [Related]
20. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
Martín M; Esteva FJ; Alba E; Khandheria B; Pérez-Isla L; García-Sáenz JA; Márquez A; Sengupta P; Zamorano J
Oncologist; 2009 Jan; 14(1):1-11. PubMed ID: 19147689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
